Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
Status:
Suspended
Trial end date:
2023-02-22
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the
safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric
participants with nosocomial pneumonia (NP).
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ceftolozane Ceftolozane, tazobactam drug combination Cephalosporins Penicillanic Acid Tazobactam